Cardinal Health (NYSE: CAH) announced today the launch of its next generation NTrainer™ System 2.0, a medical device designed to help premature and newborn infants develop the oral coordination skills important for the transition to independent feeding faster, thus helping…
The “Global Urinary Incontinence Market (2023 Edition) – Analysis By Incontinence Type (Stress, Urge, Mixed, Others), Product Type, End-user, By Region, By Country: Market Size, Insights, Competition, Covid-19 Impact and Forecast (2023-2028)” report has been added to ResearchAndMarkets.com’s offering. The Global Urinary Incontinence Market…
DexCom, Inc. (Nasdaq: DXCM), global manufacturer of systems for real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Real-Time Continuous Glucose Monitoring System (rt-CGM) is the first and only CGM to connect to the Omnipod 5 AID…
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of…
Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval of its TIGERTRIEVER revascularization device. With this milestone approval from the National Medical Products Administration (NMPA), TIGERTRIEVER becomes the first device to offer patient-specific solutions to remove blood clots from the brain…
Longaevus Technologies, announces the spin-off of Elastin Biosciences following breakthrough preclinical results of 3 of its assets. Longaevus Technologies is a company builder with dedicated to longevity, with an all-round approach to reversing aging based on its multiple hallmarks. Longaevus…
Novartis today announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9, ORION-10, ORION-11 and ORION-3 trials. The data demonstrated that with twice-yearly* dosing, Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction…
Sandoz, a global leader in generic and biosimilar medicines, has successfully completed the acquisition of worldwide brand rights for leading systemic antifungal agent Mycamine ® (micafungin sodium, Funguard® in Japan) from Astellas. Through this acquisition of the leading global echinocandin, one of three…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, being evaluated for…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor…
Serengen and Deargen are excited to announce their collaboration to accelerate the drug discovery process. This strategic partnership brings together Serengen’s novel DNA encoded library (DEL) technology with Deargen’s leading AI-driven drug discovery platform, known as DearDTI. The world of drug discovery is…
The “Esophagoscopes Market Size by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures and Forecast to 2033” database has been added to ResearchAndMarkets.com’s offering. This report was built to visualize quantitative market trends within Endoscopy Devices therapeutic area. The model discusses…